Prolonged MLN0905 exposure produced a model-dependent senescence-associated phenotype. After two weeks, HCT116, A549 and SW480 cells showed increased β-galactosidase staining with enlarged, flattened morphology; HT-29 cells did not show the same phenotype under their tested condition. These findings support context-dependent cellular responses rather than a uniform senescence outcome. [2]
Live-cell PLK isozyme target engagement
Cell-based study · Adherent HEK293 cells expressing N-terminal NanoLuc fusions of human PLK1, PLK2 or PLK3 [1]
MLN0905 displaced the intracellular tracer preferentially from PLK1. These are live-cell target-engagement IC50 values, not cell-free enzyme inhibition or cell-viability IC50 values. The model uses engineered fusion proteins in HEK293 cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response testing; full MLN0905 dilution series is not specified in the retrieved main text.
- Exposure duration
- 2 h equilibration at 37 °C before BRET measurement
- Method
- Live-cell NanoBRET competition assay with probe 11; extracellular NanoLuc inhibitor suppresses signal from membrane-compromised cells.
- Vehicle
- Inhibitors prepared as DMSO stocks and diluted in Opti-MEM; final DMSO percentage not specified.
- Reported limits
- Table 1 states an average of two technical replicates ±15%; this is not labeled SD or SEM. Independent biological replicate number and full MLN0905 titration range are not specified.
Methods and source locations
Compound reported in the paper: MLN0905; Compound label in the paper: MLN0905 in Table 1
Evidence applies to named MLN0905 in this engineered cell assay and does not validate an Adooq lot.
Table 1, MLN0905 row and footnote c; Sections 2.2–2.3, 4.1 first paragraph and 4.2.1–4.2.2; Discussion assay limitations
Intracellular PLK1 target engagement: NanoBRET tracer displacement; probe 11 at 0.2 µM — Table 1, MLN0905 row and footnote c; Sections 2.2–2.3, 4.1 first paragraph and 4.2.1–4.2.2; Discussion assay limitations
Intracellular PLK2 target engagement: NanoBRET tracer displacement; probe 11 at 1.0 µM — Table 1, MLN0905 row and footnote c; Sections 2.2–2.3, 4.1 first paragraph and 4.2.1–4.2.2; Discussion assay limitations
Intracellular PLK3 target engagement: NanoBRET tracer displacement; probe 11 at 1.0 µM — Table 1, MLN0905 row and footnote c; Sections 2.2–2.3, 4.1 first paragraph and 4.2.1–4.2.2; Discussion assay limitations
Model-dependent senescence-associated phenotype after prolonged treatment
Cell-based study · HCT116, A549, SW480 and HT-29 human cancer cell lines [2]
After two weeks of continuous MLN0905 treatment, HCT116, A549 and SW480 cells showed increased β-galactosidase-positive area and enlarged, flattened morphology relative to vehicle controls. HT-29 did not show the same staining or morphology. These endpoints support a senescence-associated phenotype; this experiment does not establish irreversible arrest after drug withdrawal.
Literature-Reported Treatment Conditions
- Treatment concentration
- HCT116: 50 nM; A549: 30 nM; SW480 and HT-29: 20 nM
- Exposure duration
- Two weeks continuously, with one medium change; β-galactosidase staining for 24 h afterward.
- Method
- Cell treatment followed by β-galactosidase staining and morphology/image analysis.
- Vehicle
- DMSO control (Figure 5B); final DMSO concentration for this experiment not specified.
- Reported limits
- Replicate unit and number are not explicitly specified for Figure 5A–B; plotted points were not assumed to be independent experiments. Exact positive-area means were not read from the graph.
Methods and source locations
Compound reported in the paper: MLN0905; Compound label in the paper: MLN0905 in Figure 5A–B
Model- and exposure-specific cellular findings for MLN0905; no supplier-lot equivalence or universal cell-fate claim.
Figure 5A–B and caption; Results: Plk1 inhibition, in vitro, leads to cellular senescence; Methods: Cell culture and β-Galactosidase staining
HCT116 β-galactosidase-positive area after 50 nM MLN0905: β-galactosidase staining and image analysis; Figure 5B reports mean ±SD and two-tailed Mann–Whitney test. — Figure 5A–B and caption; Results: Plk1 inhibition, in vitro, leads to cellular senescence; Methods: Cell culture and β-Galactosidase staining
A549 β-galactosidase-positive area after 30 nM MLN0905: β-galactosidase staining and image analysis; Figure 5B reports mean ±SD and two-tailed Mann–Whitney test. — Figure 5A–B and caption; Results: Plk1 inhibition, in vitro, leads to cellular senescence; Methods: Cell culture and β-Galactosidase staining
SW480 β-galactosidase-positive area after 20 nM MLN0905: β-galactosidase staining and image analysis; Figure 5B reports mean ±SD and two-tailed Mann–Whitney test. — Figure 5A–B and caption; Results: Plk1 inhibition, in vitro, leads to cellular senescence; Methods: Cell culture and β-Galactosidase staining
HT-29 senescence-associated staining and morphology after 20 nM MLN0905: Qualitative Figure 5A microscopy and accompanying Results; HT-29 has no quantitative panel in Figure 5B. — Figure 5A–B and caption; Results: Plk1 inhibition, in vitro, leads to cellular senescence; Methods: Cell culture and β-Galactosidase staining